To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twice-daily regimen.
Ask a Question?
Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others
Please enter valid email address.
Please enter all required fields.